Achieving a safe and early discharge for patients with community-acquired pneumonia

Medical Clinics of North America

Volumn 85, Issue 6, 2001, Pages 1427-1440

  Rhew, David C ^a   Weingarten, Scott R ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Zynx Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT;

ANTIBIOTIC THERAPY; BODY TEMPERATURE; BREATHING RATE; CLINICAL FEATURE; CLINICAL PATHWAY; HEALTH CARE COST; HEALTH CARE QUALITY; HEART RATE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; LENGTH OF STAY; MEDICAL DECISION MAKING; OXYGEN SATURATION; PNEUMONIA; PRIORITY JOURNAL; REVIEW; SYSTOLIC BLOOD PRESSURE;

EID: 0034774591     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-7125(05)70389-8     Document Type: Article

References (77)

1. Early switch from intravenous to oral antibiotics in hospitalized patients with infections: A 6-month prospective study
2. Safely increasing the proportion of patients with community-acquired pneumonia treated as outpatients: An interventional trial
3. Effects of a pneumonia clinical pathway on time to antibiotic treatment, length of stay, and mortality
4. Is an observation period necessary after intravenous antibiotics are changed to oral administration?
5. Predicting the need for hospitalization of ambulatory patients with pneumonia
6. Cefuroxime and cefuroxime axetil versus amoxicillin plus clavulanic acid in the treatment of lower respiratory tract infections
7. Preoperative stay as a risk factor for nosocomial infection
8. The periodic health examination
9. Duration and route of antibiotic therapy in community-acquired pneumonia: Switch and step-down therapy
10. Oral versus intravenous antibiotics for community acquired lower respiratory tract infection in a general hospital: Open, randomised controlled trial
11. Preferences for home vs hospital care among low-risk patients with community-acquired pneumonia
12. Rules of evidence and clinical recommendations on the use of antithrombotic agents
13. Intravenous-to-oral antibiotic switch therapy: A cost-effective approach
14. Programs promoting timely sequential antimicrobial therapy: An American perspective
15. The utility of an in-hospital observation period after discontinuing intravenous antibiotics
16. An analysis of the quality and effectiveness of the discharge planning process
17. Intervention to discontinue parenteral antimicrobial therapy in patients hospitalized with pulmonary infections: Effect on shortening patient stay
18. Patient-centered pneumonia care: A case management success story
19. Effects of early discharge planning on length of hospital stay
20. A prediction rule to identify low-risk patients with community-acquired pneumonia
21. The hospital discharge decision for patients with community-acquired pneumonia: Results from the Pneumonia Patient Outcomes Research Team cohort study
22. Hospitalization decision in patients with community-acquired pneumonia: A prospective cohort study
23. Economic impact of oral ciprofloxacin following standard intravenous therapy
24. Antibiotic optimization: An evaluation of patient safety and economic outcomes
25. Antibiotic therapy in pneumonia: A comparative study of parenteral and oral administration of penicillin
26. Retrospective analysis of risk factors and prognosis in non-ventilated patients with nosocomial pneumonia
27. Clinical pathway for pneumonia: Development, implementation, and initial experience
28. Clinical and economic impact of oral ciprofloxacin as follow-up to parenteral antibiotics
29. Purpose of quality standards for infectious diseases
30. Time to clinical stability in patients hospitalized with community-acquired pneumonia: Implications for practice guidelines
31. Pharmacoeconomic benefit of antibiotic step-down therapy: Converting patients from intravenous ceftriaxone to oral cefpodoxime proxetil
32. Pharmacist-managed intravenous to oral step-down program
33. Ofloxacin in the treatment of lower respiratory tract infections: Report of a prospective, comparative trial
34. Sequential intravenous-oral administration of ciprofloxacin vs ceftazidime in serious bacterial respiratory tract infections
35. Pneumonia pathway cut charges by $2,900 per case
36. Drug prescribing and its relation to length of hospital stay
37. Prospective payment system and impairment at discharge: The 'quicker-and-sicker' story revisited
38. Symptoms in hospitalized patients: Outcome and satisfaction with care
39. The effect of intravenous-to-oral switch guidelines on the use of parenteral antimicrobials in medical wards
40. The cost of treating patients with community-acquired pneumonia
41. Evaluation of the use of cefuroxime and cefuroxime axetil in an intravenous-oral stepdown program
42. A controlled trial of a critical pathway for treatment of community-acquired pneumonia
43. Variation in length of hospital stay in patients with community-acquired pneumonia: Are shorter stays associated with worse medical outcomes?
44. Variation in length of hospital stay in patients with community-acquired pneumonia: Are shorter stays associated with worse medical outcomes?
45. Effects of a medical team coordinator on length of hospital stay
46. Sequential antimicrobial therapy - The role of quinolones
47. Guidelines for the initial management of adults with community-acquired pneumonia: Diagnosis, assessment of severity, and initial antimicrobial therapy
48. Augmentin (intravenous then oral) compared with cefuroxime followed by cephalexin for chest infections in hospitalised patients
49. Criteria-based antimicrobial i.v. to oral conversion program
50. Early transition to oral antibiotic therapy for community-acquired pneumonia: Duration of therapy, clinical outcomes, and cost analysis
51. Cost-effectiveness comparison of sequential ofloxacin versus standard switch therapy
52. Critical pathways as a strategy for improving care: Problems and potential
53. Effectiveness of a pneumonia clinical pathway: Quality and financial outcomes
54. A pharmacist-initiated program of intravenous to oral antibiotic conversion
55. Economic impact of streamlining antibiotic administration
56. Switch therapy with beta-lactam/beta-lactamase inhibitors in patients with community-acquired pneumonia
57. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia
58. Early switch from intravenous to oral antibiotics and early hospital discharge: A prospective observational study of 200 consecutive patients with community-acquired pneumonia
59. The clinical benefit of in-hospital observation in 'low-risk' pneumonia patients after conversion from parenteral to oral antimicrobial therapy
60. A prospective, multicenter study of a pneumonia practice guideline
61. Benchmark analysis of strategies hospitals use to control antimicrobial expenditures
62. Third generation cephalosporins in the parenteral to oral switch
63. Oral cephalosporins for use in a parenteral-to-oral switch programme
64. Evaluation of a critical pathway for pneumonia
65. On squeezing balloons: Cost control fails again
66. The epidemiology of delays in a teaching hospital: The development and use of a tool that detects unnecessary hospital days
67. Early switch from intravenous to oral antibiotics: Guidelines and implementation in a large teaching hospital
68. A prospective randomized study of inpatient iv antibiotics for community-acquired pneumonia: The optimal duration of therapy
69. Outcomes of a pneumonia critical path
70. Sequential therapy with cefuroxime followed by cefuroxime axetil in community-acquired pneumonia
71. Efficacy and tolerance of cefotaxime followed by cefixime versus cefotaxime alone in patients with lower respiratory tract infections
72. A guide to the treatment of lower respiratory tract infections
73. Evaluation of a pneumonia practice guideline in an interventional trial
74. Identification of low-risk hospitalized patients with pneumonia: Implications for early conversion to oral antimicrobial therapy
75. Reducing costs and hospital stay for pneumonia with home intravenous cefotaxime treatment: Results with a computerized ambulatory drug delivery system
76. Evaluation of the efficacy of sequential intravenousoral administration of pefloxacin in community-acquired lower respiratory tract infections in patients with underlying conditions
77. Development of an intravenous-to-oral route conversion program for antimicrobial therapy at a Canadian tertiary care health facility